PSTX — Poseida Therapeutics Income Statement

0.000.00%

Last trade - 00:00

HealthcareSpeculativeMid CapMomentum Trap

Annual income statement for Poseida Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

	2019 December 31st	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	PROSPECTUS	10-K	10-K	10-K	10-K
Standards:	USG	USG	USG	USG	USG
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	0	0	31.2	130	64.7
Selling / General / Administrative Expenses
Research And Development
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	85.5	127	153	190	194
Operating Profit	-85.5	-127	-122	-59.9	-130
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	-86.5	-130	-125	-63.5	-123
Provision for Income Taxes
Net Income After Taxes	-86.5	-130	-125	-64	-123
Net Income Before Extraordinary Items
Net Income	-86.5	-130	-125	-64	-123
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	-86.5	-130	-125	-64	-123
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	-1.4	-2.1	-2.32	-0.884	-1.37
Dividends per Share